This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Thomas Schürpf, Ph.D.
Associate Director, Discovery Biology at Scholar Rock

Profile

Thomas Schurpf, Ph.D. is Associate Director of Discovery Biology at Scholar Rock, Inc. His work focuses on identifying novel therapeutics that target the TGFβ1 growth factor in its molecular context. His team has identified antibodies that inhibit the activation of latent TGFβ1 in an isoform-selective manner, which may avoid dose-limiting toxicities previously identified with less selective TGFβ pathway inhibitors. Dr. Schurpf led the preclinical discovery and evaluation of SRK-181, a potent and selective inhibitor of latent TGFβ1 activation and Scholar Rock’s first product candidate in its cancer immunotherapy program. SRK-181 is currently being investigated in the DRAGON Phase 1 dose escalation and dose expansion clinical trial in patients with locally advanced or metastatic solid tumors exhibiting primary resistance to anti-PD-(L)1 therapy. Prior to joining Scholar Rock, Dr. Schurpf was a Research Fellow at Harvard University and Boston Children’s Hospital, where he investigated the conformational regulation of LFA-1 on human leukocytes and elucidated the mechanism of action of natalizumab, an antibody approved to treat relapsing forms of multiple sclerosis. Dr. Schurpf earned his Ph.D. degree from ETH Zurich, Switzerland, and is an inventor on multiple issued patents and patent applications and an author on multiple peer-reviewed publications.

Agenda Sessions

  • Inhibition of TGFβ1 Activation with SRK-181 Overcomes Primary Resistance to Checkpoint Inhibition Therapy

    On Demand
  • Transforming Therapeutic Targets

    10:15am